Atlanta Multiple Myeloma Symposium: Registration is OPEN
We would like to invite you to attend the 2nd Annual Atlanta Multiple Myeloma Symposium (AMMS) on Saturday, March 5, 2022, at the Intercontinental in Atlanta. This one-day meeting will address the latest strategies and state-of-the-art approaches for managing patients with multiple myeloma and other plasma cell disorders. Join us and our expert roster of faculty at this pivotal educational event.
We Welcome Dr. Lizamarie Bachier-Rodriguez, MD, to The Blood and Marrow Transplant Group of Georgia and The Northside Cancer Institute.
On October 18, 2021, Dr. Bachier-Rodriguez joined The Blood and Marrow Transplant Group of Georgia and the Northside Cancer Institute’s Blood and Marrow Transplant, Leukemia and Immunotherapy Programs. Dr. Bachier-Rodriguez has extensive experience taking care of patients with complex blood and hematological malignancies.
Assistant Professor of Medicine
• Albert Einstein College of Medicine/Montefiore Medical Center
Advanced Bone Marrow Transplant Fellowship:
• Memorial Sloan Kettering Cancer Center, New York, NY
Hematology Oncology Fellowship:
• Weil Cornell Medicine, New York, NY
Postgraduate Training:
• Internal Medicine Residency, Hospital of the University of Pennsylvania, Philadelphia, PA
Board Certification:
• Oncology and Hematology
Dr. Bachier-Rodriguez is accepting new patients. Please call 404.255.1930 to refer a patient or speak to a physician.
National Leaders in Allogeneic Transplantation
For an 12th consecutive year, The Blood and Marrow Transplant (BMT) Program at Northside Hospital Cancer Institute has been recognized as having among the best survival outcomes in the United States for bone marrow transplants.
NH-BMT is the ONLY adult BMT program in the United States that achieved one year Allogeneic transplant survival outcomes that significantly exceeded their expected survival rate for the last 12 consecutive reporting cycles, is the largest Allogenic program in Georgia, and the only transplant center in Georgia to exceed survival outcomes. The one-year survival of Allogeneic patients transplanted at Northside was 80.8%.*
For additional information, click Survival Data.
Northside BMT and Leukemia Programs to Present at the ASH 2021 Annual Meeting
Congratulations to our entire BMT and leukemia staff members’ commitment to enrolling our BMT and leukemia patients to leading-edge clinical research trials that has resulted in better survival outcomes and quality of life.
At the 2021 ASH Meeting, our physicians and Pharm D staff members will present the following:
Six oral presentations: Two NH program and four collaborative oral presentations
Fifteen poster presentations: Five NH program and ten collaborative poster presentations
Please click here to review accepted ASH 2021 oral and poster presentations.
Dr. Scott Solomon and Our Mutliple Myeloma Patient, Bryon Daily, are Featured in the Leukemia & Lymphoma Society’s Recent Patient-Doctor Perspectives Podcast.
Our BMT GVHD Team Presents at the nbmtlink’s Chronic Graft Versus Host Disease Webinar
Congratulations to Connie Sizemore, Pharm. D., Latasha Mccoy, BSN,RN and Dawn Speckhart, PhD, who led a recent nbmtlink’s webinar on Chronic Graft vs. Host Disease and its impact on post allogeneic patients’ lives.
Please click here to review their presentations.
September is Blood Cancer Awareness Month
We would like to thank our patients, caregivers and team members who continuously support our nationally recognized BMT/Leukemia/Immunotherapy Programs. Our BMT Program is the ONLY adult program in the U.S. that achieved survival outcomes that significantly exceeded their expected survival rate for the last 12 consecutive reporting cycles.
Please click the images above to view Lindsay Stead’s and Caroline Campbell's BMT and Leukemia patient testimonials.
We Congratulate Katherine Welsh on her Five Year Leukemia/BMT Anniversary
and her Son Michael’s Fifth Birthday
To read more of Katherine and her son’s amazing journey, please Click here.
Now Available: 2021 Transplant Consultation Timing Guidelines
The 2021 Transplant Consultation Timing Guidelines identify appropriate allogeneic or autologous HCT referral timing based on disease characteristics. Access the guidelines online, as a PDF or in the mobile app.
The NMDP/Be the Match and the American Society for Transplantation and Cellular Therapy (ASTCT) jointly develop the guidelines. They are based on current clinical practice, medical literature, National Comprehensive Cancer Network© (NCCN) Guidelines for the treatment of cancer and evidence-based reviews.
WebMD Features Dr. Larry Morris and Ray Gillespie, a Northside Immunotherapy Program CAR T-cell Patient
To refer a CAR T-cell patient, please call 404-255-1930 or visit http://www.bmtga.com/immunotherapy-program-at-northside/
Dr Holland’s CAR T-cell therapy for relapsed/refractory Non-Hodgkin’s Lymphoma, Presentation is Now Available
The Immunotherapy Program at Northside Hospital Now Offers All Four FDA- Approved CAR T-cell Products for B-cell Malignancies
The Immunotherapy Program at Northside Hospital Now Offers Abecma® CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
Congratulation to the NH-BMT Program
Successful BMT CTN Grant Renewal 2017 – 2023
NH-BMT program achieved BMT CTN Core Center Grant renewal funding for years 2017 - 2023. Past performance, current application, and PI leadership contributed to the grant renewal. NH-BMT applied as a consortium with University of Miami and Levine Cancer Institute. The National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) provide BMT CTN research grant funding.
Achieving this award is a validation of the efforts of each person in the program, the support of the administration, and leadership of the BMTGA physicians. For further information, please read Press Release.
Advances in Immunotherapy for Cancer: Novel Phase I Clinical Research Trial Open for Enrollment
Advances in Immunotherapy for Cancer: Novel Phase I Clinical Research Trial Open for Enrollment
Advances in Immunotherapy for Cancer: Novel Phase I Clinical Research Trial Open for Enrollment
Advances in Immunotherapy for Cancer: Novel Phase I Clinical Research Trial Open for Enrollment
Advances in Immunotherapy for Cancer: Novel Phase I Clinical Research Trial Open for Enrollment
Post- Blood and Marrow Transplant Immunization Schedule- What You Need to Know
After blood and marrow transplant, patients will need to be re-immunized with all childhood vaccinations due to their new immune systems being immature and vulnerable to diseases/infections. It is recommended that post-transplant patients begin their vaccination schedule six months after transplant unless clinically contraindicated. The Centers for Disease Control (CDC), recommends the following:
- Inactivated influenza vaccine should be administered beginning at least 6 months after HCT and annually thereafter for the life of the patient.
- Sequential administration of 3 doses of pneumococcal conjugate vaccine is recommended, beginning 3-6 months after the transplant, followed by a dose of PPSV.
- A 3-dose regimen of Hib vaccine should be administered beginning 6 months after transplant; at least 1 month should separate the doses.
- MMR vaccine should be administered 24 months after transplant if the HCT recipient is immunocompetent.
- If a decision is made to vaccinate with varicella vaccine, the vaccine should be administered a minimum of 24 months after transplantation if the HCT recipient is presumed to be immunocompetent.
Please click here to view the NH-BMT post-transplant vaccination schedule recommended for both autologous and allogeneic transplant recipients. For more specific information, see Tomblyn M, Chiller T, Einsele H, et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective [1.9MB, 96 pages]. Biol Blood Marrow Transplant 15:1143-1238;2009 or visit http://www.cdc.gov/vaccines.
